Drug intelligence / Profile preview

TDNM

Development stage: Preclinical
Modality: Small Molecules

Overview

TDNM is a synthetic analogue of cord factor, specifically 6,6'-dideoxy-6,6'-bis-mycoloylamino-alpha,alpha-trehalose. It is described as a less toxic cord factor analogue that has demonstrated potent antitumour activity, particularly when combined with other immunomodulatory agents like 6-O-stearoyl muramyldipeptide (L18-MDP) or synthetic lipid A of Escherichia coli (compound 506). Its mechanism of action is related to its immunomodulatory properties, leading to the regression of transplantable line-10 hepatocellular carcinoma in experimental models.

Other names: 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose

Beyond the preview

Go deeper on TDNM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TDNM.

Explore the full profile